Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1455002 | 0.85 | ALDH1A1 (0.33) | ALDH1A1LMNAALOX5PPARGPPARA | |
| SCHEMBL1454341 | 0.81 | ALDH1A1 (0.33) | ALDH1A1LMNAALOX5PPARGPPARA | |
| SCHEMBL1454533 | 0.80 | ALDH1A1 (0.36) | ALDH1A1MAPTKMT2ALMNAPTGES | |
| SCHEMBL11448460 | 0.79 | PTGES (0.39) | ALDH1A1MAPTKMT2ALMNAPTGES | |
| SCHEMBL14635883 | 0.76 | HPGD (0.41) | ALDH1A1MAPTKMT2ALMNAPTGES | |
| SCHEMBL1453219 | 0.75 | ALDH1A1 (0.35) | ALDH1A1KMT2ALMNAPOLBHTT | |
| SCHEMBL28437615 | 0.75 | HPGD (0.44) | ALDH1A1MAPTPTGESALOX5PPARG | |
| SCHEMBL1455294 | 0.73 | HPGD (0.38) | ALDH1A1MAPTKMT2ALMNAPTGES | |
| SCHEMBL12856933 | 0.73 | PPARG (0.47) | ALDH1A1MAPTKMT2ALMNAPTGES | |
| SCHEMBL415481 | 0.71 | KMT2A (0.44) | ALDH1A1MAPTKMT2ALMNAPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910617-B2 | Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound | SANKYO COMPANY, LIMITED (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20070191468-A1 | Amino alcohol compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1733724-A1 | AMINO ALCOHOL COMPOUND | Sankyo Company, Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191468-A1 | Amino alcohol compound | ADH1A, ADH1C, BCAT1 | ALDH1A1 62/4885MAPT 2680/4885KMT2A 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.